On August 3, 2023, BIO-RAD LABORATORIES ($NYSE:BIO) reported their second quarter fiscal year 2023 earnings results, with a total revenue of $681.1 million, a 1.4% decrease from the prior year’s quarter. Net income for the quarter was -$1162.2 million, as compared to the -$927.2 million from the previous year.
The company’s stock opened at $402.9 and closed at $401.8, down 0.5% from its prior closing price of $403.8. BIO-RAD LABORATORIES attributed much of its success to its advanced product development and innovation. The company has continued to invest in the development of new products and services, which have been well-received by customers.
Additionally, BIO-RAD LABORATORIES has maintained a focus on cost control to optimize production and distribution, enabling the company to remain competitive in the market. Overall, BIO-RAD LABORATORIES reported strong and encouraging second-quarter earnings results despite the 0.5% decrease in stock prices. The company is confident in its ability to maintain its financial performance in the coming months. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Bio-rad Laboratories. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bio-rad Laboratories. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bio-rad Laboratories. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Bio-rad Laboratories are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Bio-rad Laboratories Stock Fair Value
At GoodWhale, we’ve been closely analyzing the fundamentals of BIO-RAD LABORATORIES. After a comprehensive review of the company’s financials, we can report that we have set the fair value of BIO-RAD LABORATORIES share at around $459.2, based on our proprietary Valuation Line. Currently, BIO-RAD LABORATORIES stock is trading at $401.8, which is slightly below our fair value estimation and thus, in a sense undervalued by 12.5%. This presents an opportunity for investors to buy the stock at an attractive price. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the medical technology industry is fierce. Among the major players are Bio-Rad Laboratories Inc and its competitors Lexagene Holdings Inc, Co-Diagnostics Inc, Suzhou Basecare Medical Corp Ltd. All of these companies are vying for a share of the market by offering innovative products and services.
– Lexagene Holdings Inc ($TSXV:LXG)
Lexagene Holdings Inc is a biotechnology company that develops and commercializes diagnostic solutions for the detection of pathogens. The company has a market cap of 19.42M as of 2022 and a return on equity of -164.09%. The company’s products are used in a variety of industries, including healthcare, agriculture, and food safety.
Co-Diagnostics Inc is a molecular diagnostics company that develops, manufactures, and markets diagnostic tests. The company has a market cap of 103.71M as of 2022 and a return on equity of 12.67%. Co-Diagnostics Inc develops and manufactures diagnostic tests for a range of infectious diseases, including Zika virus, dengue fever, and chikungunya. The company’s products are used by healthcare providers, laboratories, and research institutions around the world.
– Suzhou Basecare Medical Corp Ltd ($SEHK:02170)
With a market cap of 790.49M as of 2022, Suzhou Basecare Medical Corp Ltd has a ROE of -4.34%. The company is engaged in the research and development, production, and sale of medical devices. Its products include surgical gowns, medical masks, and medical gloves.
Investors may be interested in the latest earnings results of BIO-RAD LABORATORIES for the second quarter of their fiscal year 2023. Total revenue for the quarter decreased by 1.4% compared to the same period in the previous year. Net income fell to -$1162.2 million from -$927.2 million in the prior year. While this news may be discouraging, investors may find it useful to monitor the company’s efforts to increase revenue and profitability over time, such as investments in research and development, expanding product offerings, and other strategies.